Clinical trials: Major Depressive Disorder (MDD)
Major Depressive Disorder
Canadian Biomarker Integration Network for Depression (CAN-BIND) - Validation Study
This is a validation study that will replicate a completed study designed to assess biomarkers of treatment response to standard antidepressant treatment.
- Trial name
- NCT04162522
- Testing
- Escitalopram, Brexpiprazole
- Where
- 6 sites in Canada
- Volunteers
- 1 people
- Sponsor
- University Health Network, Toronto
Major Depressive Disorder (MDD)
A Study to Evaluate the Efficacy and Safety of REL-1017 As Adjunctive Treatment of Major Depressive Disorder (MDD)
Study Overview This clinical trial is a Phase 3 research study designed to test the safety and effectiveness of an investigational drug called REL-1017 (esmethadone HCl).
- Trial name
- NCT06735079
- Testing
- REL1017 (esmethadone HCI) (active drug)
- Where
- 2 sites in Italy, Switzerland
- Sponsor
- MGGM LLC
Major Depressive Disorder, Insomnia
A Study of Eszopiclone Co-administered With Venlafaxine in Subjects With Major Depressive Disorder and Insomnia
To evaluate the antidepressant effect of adjunctive treatment with Eszopiclone in subjects receiving venlafaxine for the treatment of Major Depressive Disorder (MDD).
- Trial name
- NCT00435279
- Testing
- Eszopiclone, Venlafaxine
- Where
- 69 sites in Austria, Croatia and 8 more
- Volunteers
- 678 people
- Sponsor
- Sumitomo Pharma America, Inc.
Major Depressive Disorder
Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-911 in Healthy Subjects
The purpose of the study is to investigate the effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-911 in Healthy Subjects
- Trial name
- SUVN-911 (NCT03551288)
- Testing
- SUVN-911
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Suven Life Sciences Limited
Depression, Depressive Disorder
Assessment of the Safety and Effectiveness of Cortical Stimulation in Subjects With Major Depressive Disorder
The purpose of this study is to assess the safety and effectiveness of cortical stimulation to the cerebral cortex of subjects who have suffered from treatment-resistant depression and have failed routine attempts at controlling…
- Trial name
- PROSPECT (NCT00380042)
- Testing
- Cortical Stimulation
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Northstar Neuroscience
Major Depressive Disorder
Repurposing of Dextromethorphan as an Adjunct Therapy in Patients With Major Depressive Disorder
Therapeutic latency, lack of efficacy, and adverse drug reactions are the major concerns in current antidepressant therapies. One-third of the patients with major depressive disorder do not respond to conventional antidepressants…
- Trial name
- NCT05181527
- Testing
- Selective Serotonin Reuptake Inhibitors, Dextromethorphan
- Where
- India
- Volunteers
- 60 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
PTSD, Alzheimer Disease
First-In-Human (FIH), Single Ascending Dose (SAD) Study of FluoroEthylNorMemantine (FENM)
The goal of this First-In-Human (FIH) trial is to learn about safety and PharmacoKinetics (PK) in healthy adult volunteers. The main questions it aims to answer are: What is the safety of single ascending doses of the…
- Conditions
- PTSD, Alzheimer Disease, Brain Diseases, Neuro-Degenerative Disease
- Trial name
- NCT05921929
- Testing
- Fluoroethylnormemantine (FENM)
- Where
- Belgium
- Volunteers
- healthy volunteers welcome
- Sponsor
- ReST Therapeutics
Bipolar Disorder, Schizophrenia
Life Goals Behavioral Change to Improve Outcomes for Veterans With Serious Mental Illness
Persons with serious mental illness are at increased risk of cardiovascular disease. The goals of this study are to test a treatment, Life Goals Collaborative Care to help promote health behavior change and to get feedback from…
- Conditions
- Bipolar Disorder, Schizophrenia, Major Depressive Disorder, Chronic Affective Disorders
- Trial name
- NCT01244854
- Testing
- Life Goals Collaborative Care
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- VA Office of Research and Development
Major Depressive Disorder
Invasive Decoding and Stimulation of Altered Reward Computations in Depression Patients
Novel invasive neurostimulation stimulation strategies through neurosurgical interventions are emerging as a promising therapeutical strategy for major depressive disorder.
- Trial name
- NCT05239780
- Testing
- Brain stimulation
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Major Depression
Evaluation of the H-Coil Transcranial Magnetic Stimulation(TMS) Device- Augmentation for Drug Resistant Depression
There is a general consensus of efficacy of TMS in treatment of major depression,yet results are not satisfying.A new coil ("H"-coil, recently invented in Weizmann Institute of Science, Neurobiology Department, Rehovot, Israel)…
- Trial name
- NCT00577070
- Testing
- TMS
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- BeerYaakov Mental Health Center
Major Depressive Disorder
The Efficacy and Safety of Task-state-based Temporal Interference Stimulation (TI) in the Treatment of Patients With Depression
This study intends to investigate the intervention efficacy of temporal interference stimulation (TI) on mood symptoms in depressed patients, as well as to explore the neuroimaging mechanisms of TI improvement in depressed…
- Trial name
- NCT06826469
- Testing
- Temporal Interference Stimulation
- Where
- China
- Volunteers
- 43 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Major Depressive Disorder
Phase 1 Study to Assess the Safety/Tolerability of Brexpiprazole as Adjunctive Therapy in Elderly Subjects With Major Depressive Disorder
The purpose of this study is to assess the safety and tolerability of ascending multiple oral doses of brexpiprazole as adjunctive therapy in the treatment of elderly subjects with MDD.
- Trial name
- NCT01670279
- Testing
- Brexpiprazole
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Depression
Org 24448 to Treat Major Depression
This study will evaluate the effectiveness of the experimental drug, Org 24448, for short-term treatment of depression. It will examine the effects of the drug on symptoms, such as low mood and persistent sadness, poor sleep and…
- Trial name
- NCT00113022
- Testing
- Org 24448
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- National Institute of Mental Health (NIMH)
Schizophrenia, Schizoaffective Disorder
Mediators and Moderators of Treatment Outcome in Recent-Onset Psychosis
Multifamily group psychoeducation [MFG] and group cognitive behavioral therapy [GCBT] are evidence-based treatments for first episode psychosis.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder With Psychotic Features, Major Depression With Psychotic Features
- Trial name
- NCT01570972
- Testing
- Group Cognitive Behavioral Therapy, Multifamily Group Psychoeducation
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- University of Arizona
Major Depressive Disorder, Major Depressive Episode
MRS and Medication Response: A Pilot Study
We hope to demonstrate that magnetic resonance spectroscopy can detect brain concentration levels of paroxetine (Paxil) or citalopram (Celexa) or escitalopram (Lexapro) in depressed patients.
- Conditions
- Major Depressive Disorder, Major Depressive Episode, Major Depressive Disorder, Recurrent, Major Depression Mild
- Trial name
- NCT03254342
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Stanford University
Depression
Paroxetine/Bupropion in Suicide Attempters/Ideators With Major Depression
The primary study comparing effectiveness for suicidal ideation and/or behavior of two antidepressant medications in depressed patients who have attempted suicide or are currently experiencing suicidal thoughts has been…
- Trial name
- NCT00429169
- Testing
- Paroxetine, Bupropion
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- New York State Psychiatric Institute
Depressive Disorder
An Investigation of the Antidepressant Efficacy of the 5-HT2A Antagonist, M100907, in Combination With Citalopram in Treatment Resistant Depression
This study will examine whether a highly specific and powerful 5-hydroxytryptamine 2A (5-HT2A) antagonist, M100907, combined with escitalopram, is responsible for an antidepressant effect.
- Trial name
- NCT00070694
- Testing
- MDL100.907
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- National Institute of Mental Health (NIMH)
Major Depressive Disorder, Mood Disorders
Psychobiological Markers to Improve Diagnosis and to Predict Affective Episodes in Bipolar Disorder
This trial has two studies. In study 1, the investigators will explore the relationships between three psychobiological factors (sleep patterns, motor activity, and decision-making ability).
- Conditions
- Major Depressive Disorder, Mood Disorders, Bipolar Disorder (BD)
- Trial name
- MoodCatcher (NCT07427966)
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Karolinska Institutet
Major Depression, Generalized Anxiety Disorder
Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months
The purpose of this study is to explore the changes in metabolic parameters in patients treated with escitalopram for six months for major depression, generalized anxiety disorder or panic disorder, with or without agoraphobia.
- Conditions
- Major Depression, Generalized Anxiety Disorder, Panic Disorder
- Trial name
- NCT00711737
- Where
- Singapore
- Volunteers
- 27 people
- Sponsor
- Changi General Hospital
Depression
Dose-Response Effect Exercise and Depression
The present study aims to address gaps in the literature by evaluating the objectively measured dose-response relationship between exercise and depression symptoms; examining changes in resting (Brain-derived Neurotrophic Factor)…
- Trial name
- NCT06166095
- Testing
- high-dose, Walking attention control, moderate-dose
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- University of Central Florida